 This is an open-label all people know the identity of the intervention, multicenter when more than one hospital or medical school team work on a medical research study study of ICZ in participants with onychomycosis. The present study consists of 2 periods: Screening period up to Week minus 2 and Treatment period up to Week 49. The ICZ will be administered in 3 cycles Week 1, Week 5 and Week 9 and each cycle will consist of taking 2 capsules of 100 milligram mg each, orally, twice daily, continuously for 1 week. Total duration of treatment will be of 49 weeks. Efficacy will primarily be evaluated by percentage of participants showing 10 percent or higher response in SCIO Score. Participants safety will be monitored throughout the study. 